Home / Reports


Brazil looks to follow-on biological products to contain costs

Brazil’s Government is looking at measures to control the rising cost of healthcare. With increasing demand for life-saving biologicals the government is considering follow-on biological products as a more cost-effective option [1].

Generics gaining ground in French pharmaceutical market

The French pharmaceutical market is forecast to grow by a miniscule amount in the coming years due to the growing influence of generics in the country.

US pay-for-delay deals decrease in 2013

During 2013, companies filed a total of 145 final patent dispute settlements, of which 29 were potentially anticompetitive or ‘pay-for-delay’ agreements between brand-name and generics companies, according to a new report released on 22 December 2014 by the US Federal Trade Commission (FTC).

Generics still cost more in Canada, but prices decreasing

A report issued in December 2014 by Canada’s Patented Medicine Prices Review Board (PMPRB) finds that the prices of generics in Canada have decreased significantly in recent years. However, Canadians are still paying more for their generics than patients in many other countries.

EU problematic patent settlements stabilize

The number of patent settlements between originator and generics companies concluded during 2013 has reduced compared to 2012. While the number of problematic or so-called ‘pay-for-delay’ deals have stabilized compared to 2012.

Biosimilars could save US$44.2 billion over 10 years

Introducing biosimilars of complex biologicals used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologicals in the US by US$44 billion over the next decade, according to an analysis carried out by the RAND Corporation.

UK uses less brand-name medicines per person

The UK uses fewer brand-name medicines per person than many other countries, but this means that the country tends to use older medicines rather than the latest ones, according to a new report.

Generics makers challenging more patents

In recent years generics makers are becoming bolder and challenging more patents on originator drugs. In fact, litigation regarding patents on pharmaceuticals is on the rise, particularly when it comes to newer drugs.

Growth in Netherlands pharma market held back by generics policies

The pharmaceutical market in The Netherlands will rise slowly from approximately US$6.7 billion in 2014 to US$7.2 billion by 2020. Growth is being restricted by the government’s focus on generics as a cost-containment tool, according to research and consulting firm GlobalData.

Biosimilars use in Europe varies widely

Use of biosimilars in Europe varies widely between countries and therapy areas, according to a report published by IMS Health in October 2014.

Generics News Research General


Biosimilars News Research General